SuperworthXeris Biopharma price to sales ratio XERS
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 5.5×
- 4-year median
- 2.9×
- Against its 4-year history
- 97th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 1.4× to 6.4×
- Peer median
- 1.8×
Xeris Biopharma's price to sales ratio is 5.5× as of Oct 23, 2026.
That is above its 4-year median of 2.9×, higher than on 97% of days in the last 4 years.
Over that time it ranged from 1.4× in Jan 2023 to 6.4× in Oct 2025.
The median for 10 large drugmakers of a similar size is 1.8×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.5× | 3.2× | 5.7× |
| 2025 | 4.6× | 2.5× | 6.4× |
| 2024 | 2.7× | 1.5× | 2.9× |
| 2023 | 2.1× | 1.4× | 3.3× |
| 2022 | 1.8× | 1.7× | 3.2× |
Against its peers
Companies in Drug Manufacturers - General nearest Xeris Biopharma's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| XERSXeris Biopharma | 5.5× |
| ANIPANI Pharmaceuticals | 1.7× |
| HRMYHarmony Biosciences | 2.2× |
| PAHCPhibro Animal Health | 1.0× |
| PBHPrestige Consumer Healthcare | 2.0× |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 1.9× |
| NRIXNurix Therapeutics | 3.9× |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OGNOrganon | 0.6× |
| Peer median | 1.8× |
Where Xeris Biopharma ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Xeris Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.